Linaclotide - CAS 851199-59-2
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
Linzess; Constella; 11: PN: WO2008151257 SEQID: 55 claimed protein; 13: PN: WO2008151257 SEQID: 57 claimed protein; 18: PN: WO2015054500 SEQID: 72 claimed protein; 1: PN: WO2014131024 SEQID: 55 claimed protein; 1: PN: WO2015054500 SEQID: 55 claimed protein; 2074: PN: US20090062207 SEQID: 3 claimed protein; 3: PN: WO2015054500 SEQID: 57 claimed protein; 40: PN: WO2010065751 SEQID: 55 claimed protein; 42: PN: WO2010065751 SEQID: 57 claimed protein; 55: PN: US20100152118 SEQID: 55 claimed protein; 55: PN: WO2011069038 SEQID: 55 claimed sequence; 55: PN: WO2012037380 SEQID: 55 unclaimed protein; 55: PN: WO2015054649 SEQID: 55 claimed protein; 57: PN: WO2011069038 SEQID: 57 claimed sequence; 57: PN: WO2012037380 SEQID: 57 claimed protein; 7: PN: WO2015054500 SEQID: 61 claimed protein
CAS Number:
Linaclotide is a peptide agonist of guanylate cyclase 2C that is undergoing clinical trials for use in treating abdominal pain in patients with irritable bowel syndrome (IBS) accompanied by constipation. The drug also has promising outlooks for the treatment of gastroparesis, ulcerative colitis, chronic intestinal pseudo-obstruction (CIPO), and inertia coli as well.
Molecular Weight:
Molecular Formula:
Quality Standard:
In-house Standard
Certificate of Analysis-Linaclotide 851199-59-2 B15LNCT0907  
Canonical SMILES:
Guanylate Cyclase
Size Price Stock Quantity
50 mg $698 In stock
100 mg $998 In stock
Bulk Inquiry
Chemical Structure
CAS 851199-59-2 Linaclotide

Related Guanylate Cyclase Products

CAS 329773-35-5 Cinaciguat

(CAS: 329773-35-5)

An experimental drug as an an activator of sGC in an NO-independent manner (Kd = 3.2 nM).

(CAS: 1354041-91-0)

IWP-051 is a soluble guanylate cyclase (sGC) stimulator with EC50 of 290nM. IWP-051 shows >99% plasma protein binding, high permeability, high metabolic stabili...

CAS 851199-59-2 Linaclotide

(CAS: 851199-59-2)

Linaclotide is a peptide agonist of guanylate cyclase 2C that is undergoing clinical trials for use in treating abdominal pain in patients with irritable bowel ...

CAS 625115-55-1 Riociguat

(CAS: 625115-55-1)

Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. At the moment Phase III clinical trials investigate the ...

CAS 256376-24-6 BAY 41-2272

BAY 41-2272
(CAS: 256376-24-6)

BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.

CAS 256498-66-5 BAY-41-8543

(CAS: 256498-66-5)

BAY-41-8543, with antihypertensive, is a heme-dependent stimulator of NO-independent guanylyl cyclase (sGC). In vivo, BAY 41-8543 decreases blood pressure dose-...

(CAS: 467426-54-6)

Plecanatide, also called Trulance, a synthetic analogue of uroguanylin, is a guanylate cyclase-C (GCC) agonist being developed by Synergy Pharmaceuticals for th...

CAS 254877-67-3 Ataciguat

(CAS: 254877-67-3)

Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, is a potent guanylate cyclase activator. Ataciguat has potential to treat dise...

Linaclotide acetate
(CAS: 851199-60-5)

Linaclotide is an oligo-peptide agonist of guanylate cyclase 2C. It can be used for the treatment in adults of constipation-predominant irritable bowel syndrome...

(CAS: 1350653-20-1)

Vericiguat is a potent guanylate cyclase stimulant under the development of Bayer HealthCare Pharmaceuticals. Direct stimulation of guanylate cyclase is emergin...

Reference Reading

1.Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland
Mark Fisher • Andrew Walker • Meritxell Falques. Eur J Health Econ
Linaclotide is indicated as a continuous treatment provided the patient does not discontinue due to lack of efficacy or adverse events. Clinical efficacy data were available up to 26 weeks based upon the phase III clinical trials and therefore required extrapolation for the purposes of the cost-effectiveness model. In order to capture the important differences in costs and outcomes for IBS-C treatment, with moderate data extrapolation, a 5-year time horizon was chosen. The impact of alternative time horizons was tested in sensitivity analyses, which considered shorter (1-year, and within trial) and longer (10-year) time horizons. A 4-week cycle length was chosen for consistency with monitoring requirements in the product label. Costs and health benefits were discounted at an annual rate of 3.5 % and a halfcycle correction was implemented within the model. The model structure and assumptions were validated with Scottish experts.
2.Recent Advances in the Management of Difficult Constipation
Brian E. Lacy & John Levenick & Michael Crowell. Curr Gastroenterol Rep (2012) 14:306–312
Linaclotide is a 14-amino acid peptide that stimulates intestinal guanylate cyclase type-C (GC-C) receptors (see Fig. 1;). Linaclotide is acid stable and protease resistant with low bioavailability; it is undetectable in the systemic circulation at therapeutic doses. Activation of GC-C stimulates the production of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP), which then increases the flow of electrolytes (HCO3- and Cl-) and water into the lumen of the GI tract (see Fig. 1). This is associated with faster GI transit. Stimulation of the GC-C receptor on intestinal epithelial cells and release of cGMP into the serosa leads to a reduction in visceral hyperalgesia.
3.New Options in Constipation Management
Mellar Davis & Pamela Gamier. Curr Oncol Rep (2015) 17: 55
Linaclotide is a first-in-class minimally adsorbed 14-aminoacid peptide agonist of guanylate cyclase C drug that acts on the intestinal enterocyte. The result is stimulation of chloride channels (CIC-2) and increase secretion of fluid into the gut lumen (Fig. 1). It is presently licensed for CIC and IBS-C in the USA. Oral bioavailability is 0.1 %, and less than 1 % is excreted in the stool in the first 24 h. Linaclotide undergoes proteolysis within the GI tract. However, it is resistant to pepsin, trypsin, aminopeptidases, and chymotrypsin proteolysis and thus is able to bind to duodenal and jejunal chloride channels. Linaclotide is converted to an active metabolite (MM-419447) which has the same pharmacodynamics and pharmacokinetics as the parent drug. Besides increasing luminal fluid, linaclotide also increases GI transit and reduces visceral hypersensitivity.
4.Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome
Maria I. Vazquez-Roque · Ernest P. Bouras. Adv Ther (2013) 30(3):203–11.
A randomized, double-blind, placebocontrolled efficacy trial of linaclotide was conducted to evaluate its safety in 42 patients with CC. Patients were randomized to receive 100, 300, or 1,000 μg of linaclotide or placebo once daily for 14 days. Rebound constipation was assessed in an 8-day posttreatment period. Efficacy parameters were daily bowel movements using weekly rates of spontaneous bowel movements (SBM), complete SBM (CSBM), stool consistency, straining, and complete evacuation. At all doses studied, linaclotide produced an increase in SBM and CSBM compared to the placebo.